SAGE Therapeutics Inc at Piper Sandler Healthcare Conference (Virtual) Transcript
Thank you for joining our live fireside chat during our Piper Sandler Conference. My name is Yas Rahimi. I'm a senior biotech analyst here at Piper Sandler. I am so thrilled to be featuring Sage Therapeutics. Joining me on Zoom is Barry Greene, CEO. We have quite a bit to cover in the next 30 minutes.
And first, I'm going to start off on congratulating you on two great announcements this morning. One is the data set -- the 12 months data set from SHORELINE across the 50-milligram dose group. And the second one is the unveiling of the design of the SAGE-718 Phase II DIMENSION study. For investors who may have missed that new information, it is available on the website -- of Sage's website, and we'll talk about that.
Questions & Answers
But let's kick off the discussion with the new data that's just off of the press, the 12-month SHORELINE data
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
